| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2018: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Outline of Final Research Achievements |
To determine the prevalence and pathogenic role of anti-thrombopoietin (TPO) and anti-TPO receptor (TPOR) antibodies in idiopathic thrombocytopenic purpura (ITP) patients. Anti-TPO, anti-TPOR antibodies from 132 patients with ITP and 70 healthy controls were measured by ELISA. To investigate whether anti-TPO, anti-TPOR antibodies inhibited functional interactions between TPO and TPO receptors, we examined ERKs, downstream signals induced by recombinant human TPO (rhTPO) in TPOR-expressing UT-7/TPO. Furthermore, eltrombopag was used instead of rhTPO. Anti-TPO antibodies were detected in 24% of ITP patients and anti-TPOR antibodies were detected in 10% of patients, and none of healthy controls. In half of antibody-positive samples inhibited the phosphorylation of ERK in UT-7/TPO, which might be related to the blocking of rhTPO by anti-TPO or anti-TPOR antibodies. Eltrombopag improved the phosphorylation of ERK in UT-7/TPO in the presence of functional anti-TPO or anti-TPOR antibodies.
|
